SR One Capital Management, LP
SR One Capital Management, LP reported 15 US-listed holdings worth $1.04 billion in its 13F for the quarter ended 30 June 2026, filed 12 August 2026. Its largest: Veradermics Inc (28.4%), Zenas Biopharma Inc. (12.3%) and Crispr Therapeutics AG (10.7%). Against the quarter before, it opened 3 positions, added to 1, trimmed 0 and sold out of 2.
Reported holdings$1.04B+13.5% on Q1 2026
Positions15+1 on Q1 2026
The largest ten95.1%of its reported holdings
Latest 13FQ2 2026filed 12 August 2026
OpenedAdded toHeld
The 14 largest of its 15 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Opened 3Added 1Held 11Sold out 2
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 3
- Avalyn Pharma Inc. AVLN$108.9 million
- Odyssey Therapeutics, Inc. ODTX$71.0 million
- Mobia Med Inc. MOBI$26.6 million
Added to 1
- Oric Pharmaceuticals Inc. ORIC+100,455 shares · +2%
Sold out of 2
- Arcellx Inc. ACLX$269.4 million last quarter
- Oruka Therapeutics Inc. ORKA$21.1 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Veradermics Inc MANE | 2,401,868 | $295.3 million | 28.42% | no change |
| Zenas Biopharma Inc. ZBIO | 5,037,854 | $127.9 million | 12.31% | no change |
| Crispr Therapeutics AG CRSP | 2,038,763 | $111.2 million | 10.70% | no change |
| Avalyn Pharma Inc. AVLN | 3,308,649 | $108.9 million | 10.48% | new |
| Design Therapeutics Inc. DSGN | 6,526,476 | $94.4 million | 9.09% | no change |
| Odyssey Therapeutics, Inc. ODTX | 3,794,883 | $71.0 million | 6.83% | new |
| Alumis Inc. ALMS | 1,959,896 | $55.2 million | 5.31% | no change |
| Oric Pharmaceuticals Inc. ORIC | 4,615,384 | $50.0 million | 4.81% | +100,455 |
| Mineralys Therapeutics Inc. MLYS | 1,563,966 | $42.2 million | 4.06% | no change |
| Ars Pharmaceuticals Inc. SPRY | 4,012,903 | $32.1 million | 3.09% | no change |
| Mobia Med Inc. MOBI | 1,986,072 | $26.6 million | 2.56% | new |
| Nkarta Inc. NKTX | 3,333,333 | $9.4 million | 0.91% | no change |
| Oculis Holding AG OCS | 641,022 | $8.9 million | 0.86% | no change |
| Ultragenyx Pharmaceutical in RARE | 137,753 | $4.6 million | 0.44% | no change |
| Engene Holdings Inc. ENGN | 747,750 | $1.3 million | 0.12% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.